2024
Accurate non-ceruloplasmin bound copper: a new biomarker for the assessment and monitoring of Wilson disease patients using HPLC coupled to ICP-MS/MS
Harrington C, Carpenter G, Coverdale J, Douglas L, Mills C, Willis K, Schilsky M. Accurate non-ceruloplasmin bound copper: a new biomarker for the assessment and monitoring of Wilson disease patients using HPLC coupled to ICP-MS/MS. Clinical Chemistry And Laboratory Medicine 2024, 0 PMID: 39072400, DOI: 10.1515/cclm-2024-0213.Peer-Reviewed Original ResearchLimit of detectionWilson's diseaseIntra-day precisionCopper-containing speciesTriple quadrupole inductively coupled plasma mass spectrometryQuadrupole inductively coupled plasma mass spectrometryLimit of quantificationCopper concentrationGradient elutionReaction modeIntra-dayCu-EDTAContaining speciesMass spectrometryWilson's disease patientsInductively coupled plasma mass spectrometryIntermediate precisionSerum copper concentrationICP-MS/MSPlasma mass spectrometryRegistry studyUrine copperSerum copperPatient samplesBiomarker index
2023
P20 Patterns of ALT, AST and 24-hour urine copper in adult patients with treated Wilson disease: results from an international multi-site registry at enrolment and over the course of 3 years
Camarata M, To U, Coskun A, Maciejewski K, Embel V, Ayhan E, Gonzalez-Peralta R, Ala A, Schilsky M. P20 Patterns of ALT, AST and 24-hour urine copper in adult patients with treated Wilson disease: results from an international multi-site registry at enrolment and over the course of 3 years. 2023, a25.1-a25. DOI: 10.1136/gutjnl-2023-basl.36.Peer-Reviewed Original Research
2015
Prospective Pilot Study of a Single Daily Dosage of Trientine for the Treatment of Wilson Disease
Ala A, Aliu E, Schilsky ML. Prospective Pilot Study of a Single Daily Dosage of Trientine for the Treatment of Wilson Disease. Digestive Diseases And Sciences 2015, 60: 1433-1439. PMID: 25605552, PMCID: PMC4427615, DOI: 10.1007/s10620-014-3495-6.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedChelating AgentsDrug Administration ScheduleFemaleHepatolenticular DegenerationHumansMaleMedication AdherenceMiddle AgedPatient DropoutsPatient SatisfactionPilot ProjectsProspective StudiesSurveys and QuestionnairesTime FactorsTreatment OutcomeTrientineYoung AdultConceptsSingle daily doseWilson's diseaseDaily doseDaily treatment regimenStable Wilson's diseaseProspective pilot studyLiver synthetic functionSingle daily dosageEnd of treatmentResultsAll patientsMaintenance therapyTreatment regimenDaily dosageLifelong therapyLarge trialsZinc excretionUrine copperTreatment stoppageSide effectsTreatment efficacyTrientineTherapyPatientsPilot studyDisease